Everything below concerns metabolic research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
== Role of scar tissue == Extensive scar tissue formation is a major cause of nerve entrapment, and for deep gluteal syndrome (entrapment of the sciatic nerve in the deep gluteal space), it's the most common cause. While the concept of scar tissue causing traction injuries is widely accepted, its role is more complex than strictly causing stretching injuries. Scar tissue itself is very dense and is capable of applying pressure on a nerve through bands (like a seat belt) or creating a fibrous tunnel that is capable of pinching the nerve under pressure due to its toughness. In advanced cases, scar tissue can be found in all layers of the nerve impairing blood flow and essential functions of various tissue types. This is to say that scar tissue is fairly robust in its capability to injure nerves. It can do so through traction (fibrovascular attachments), compression (osteofibrous tunnels), or can be associated with an inflammatory response that injured tissue (fibrosis).
==== Sexually transmitted infection ==== Methamphetamine use was found to be related to higher frequencies of unprotected sexual intercourse in both HIV-positive and unknown casual partners, an association more pronounced in HIV-positive participants. These findings suggest that methamphetamine use and engagement in unprotected anal intercourse are co-occurring risk behaviors, behaviors that potentially heighten the risk of HIV transmission among gay and bisexual men. Methamphetamine use allows users of both sexes to engage in prolonged sexual activity, which may cause genital sores and abrasions as well as priapism in men. Methamphetamine may also cause sores and abrasions in the mouth via bruxism, increasing the risk of sexually transmitted infection. Besides the sexual transmission of HIV, it may also be transmitted between users who share a common needle. The level of needle sharing among methamphetamine users is similar to that among other drug injection users.
Unlike birds, the ornithischian pubis also usually had an additional forward-pointing process. Ornithischia includes a variety of species that were primarily herbivores. Despite the terms "bird hip" (Ornithischia) and "lizard hip" (Saurischia), birds are not part of Ornithischia. Birds instead belong to Saurischia, the "lizard-hipped" dinosaurs—birds evolved from earlier dinosaurs with "lizard hips". The following cladogram showing the relationships of dinosaur groups is simplified after Michael Benton, 2015:
Larry Hama took over Wolverine's solo series in 1990, and exerted a major influence on how Wolverine was depicted throughout the X-Men family of publications during his run. Hama commented that he "considered the Chris Claremont, Frank Miller, and Barry Windsor-Smith [Wolverine] stories to be canon" and "pretty much ignored everything else." From 1990 to 1992, the series was usually illustrated by Marc Silvestri, who contributed to the character's rising popularity; his work on Wolverine also established him as a star artist in the industry. In issues #48-50 (November 1991-January 1992), Hama delved into Wolverine's mysterious past in the Weapon X program, which was often highly convoluted and unreliable due to the false memories implanted by the program's designers. In 1992, he revisited the Japanese setting and characters of Claremont's and Miller's earlier limited series, ending the story with the poisoning of Mariko Yashida, Logan's lover, and her mercy killing at the hands of Wolverine. During the Fatal Attractions storyline, in X-Men #25 (October 1993), the adamantium in Wolverine's body is ripped out by Magneto, using his magnetic abilities. Writers Fabian Nicieza and Scott Lobdell were inspired by a suggestion of another Marvel writer, Peter David. The story arc reveals that Wolverine has natural bone claws, in contrast to previously established narrative continuity that his claws were entirely bionic. Wolverine himself is confused by this realization, and his healing factor is also greatly weakened by recovery from this extraordinary injury.
Sources: en.wikipedia.org
== Arrest and conviction == Archerd was arrested on July 27, 1967, in Los Angeles for a threefold murder. He was convicted of killing the following: Zella Archerd, his fourth wife (July 25, 1956, two months after their wedding); Burney Archerd, his nephew (September 2, 1961, in Long Beach); and Mary Brinker Post, his seventh wife (November 3, 1966). Others suspected to be victims of Archerd are: William Jones Jr. (October 12, 1947, in Fontana), Juanita Plum Archerd, his fifth wife (March 13, 1958, in Las Vegas); and Frank Stewart (March 17, 1960). All exhibited symptoms of hypoglycemia. Archerd was sentenced to death on March 6, 1968, for three of the murder cases. The medical personnel, law enforcement, and prosecution team were unaware of the availability of an accurate and sensitive assay for blood insulin levels developed years earlier by Rosalyn Yalow in collaboration with Solomon Berson working at the Bronx Veterans Administration Hospital. Instead, they presented some unproven laboratory evidence that, in retrospect, should not have been accepted in court. In December 1970, the death sentence was upheld by the California Supreme Court. In 1972, the sentence was instead changed to life imprisonment after a ruling by the United States Supreme Court. Archerd died of pneumonia in 1977 at the age of 65.
Marguerite Yourcenar (UK: , US: ; French: [maʁɡ(ə)ʁit juʁsənaʁ] ; born Marguerite Antoinette Jeanne Marie Ghislaine Cleenewerck de Crayencour; 8 June 1903 – 17 December 1987) was a Belgian-born French novelist and essayist who became a US citizen in 1947. Winner of the Prix Femina and the Erasmus Prize, she was the first woman elected to the Académie Française, in 1980. In 1965, she was nominated for the Nobel Prize in Literature.
The identification of the heart as the seat of emotions in particular is due to the Roman physician Galen, who also located the seat of the passions in the liver, and the seat of reason in the brain. The heart also played a role in the Aztec system of belief. The most common form of human sacrifice practiced by the Aztecs was heart-extraction. The Aztec believed that the heart (tona) was both the seat of the individual and a fragment of the Sun's heat (istli). To this day, the Nahua consider the Sun to be a heart-soul (tona-tiuh): "round, hot, pulsating". In 2020, Indigenous elders including Unangan (Aleut) leader Illarion Merculieff and Hawaiian studies educator Sabra Kauka released a short film urging humanity to give the heart, rather than the intellect, a greater role in guiding action. In Catholicism, there has been a long tradition of veneration of the heart, stemming from worship of the wounds of Jesus Christ which gained prominence from the mid sixteenth century. This tradition influenced the development of the medieval Christian devotion to the Sacred Heart of Jesus and the parallel veneration of the Immaculate Heart of Mary, made popular by John Eudes.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.